Aspirin

New treatments must be approved by MHRA and NICE for NHS prescription. The MND Association, MND Scotland, and My Name’5 Doddie Foundation provide information on UK drug access routes. The NHS Medicines Repurposing Programme explores using existing drugs for new purposes, exemplified by aspirin. Charities and patients can influence access through trials and awareness. A glossary explains key terms.

DelveInsight's 'Melanoma Pipeline Insight 2024' covers 150+ companies and 170+ pipeline drugs, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, and BioNTech SE. Key therapies like Amtagvi (Iovance Biotherapeutics) received FDA fast-track approval in 2024 for metastatic melanoma. Neoadjuvant immunotherapy became standard care for stage III melanoma after ESMO 2024 updates. The report assesses therapies by product type, stage, route of administration, and molecule type, highlighting active and inactive pipeline products.

Inclusion of under-represented racial and ethnic groups in cardiovascular clinical trials is discussed, emphasizing the need for improved representativeness and diversity among participants.

Regular aspirin use may reduce pancreatic cancer risk by 40% in people with diabetes and by 20% in the general population, according to a UK study.

A multicenter, randomized, double-blind, placebo-controlled trial evaluates Ruanjian Qingmai granules' efficacy and safety in treating symptomatic PAD, aiming to improve walking ability and slow disease progression.

neffy®, the first needle-free epinephrine nasal spray for anaphylaxis, was approved by the FDA in August 2024. While many are excited about this new option, clinical trials did not test its efficacy during actual anaphylactic episodes. Providers may recommend carrying both neffy and an auto-injector, using neffy first and switching to the injector if symptoms worsen or do not improve within five minutes. Immediate ER visit is advised after epinephrine use.

Kerendia, a nonsteroidal mineralocorticoid receptor antagonist, reduced cardiovascular death risk by 16% in HF patients with ejection fraction >40% in a phase 3 trial. Hyperkalemia incidence was higher but not significant, with no hospitalizations or deaths.

Aetna, a CVS Health company, announces 2025 Medicare products focusing on core benefits for member health, offering value, choice, and affordability with $0 monthly premiums, primary care copays, and Tier 1 drug copays, plus dental, vision, hearing, and SilverSneakers benefits. Plans include Medicare Advantage, Prescription Drug, Special Needs, and Medicare Supplement products, expanding coverage to new states and counties, and integrating benefits like the Aetna Medicare Extra Benefits Card and high-value primary care providers. Prescription drug coverage is refined for transparency and cost reduction, supported by CVS Health resources such as MinuteClinic, OTC benefits, and Healthy Home Visits. Aetna also simplifies stand-alone prescription drug plan coverage and offers competitive Medicare Supplement and ancillary plans.

RESPECT2 trial assesses CCTA-guided prevention strategy vs. usual care in asymptomatic population, aiming to determine lipid management impact and subclinical CAD prevalence in Nanjing, China. Participants (40-69 years) are randomly assigned to CCTA or usual care groups, with follow-up at 6, 12 months, and annually for 5 years. Primary outcome measures medication adherence and LDL-C target achievement at 12 months.